469 SACUBITRIL/VALSARTAN REDUCES CARDIAC DECOMPENSATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS


 
 
 The impact of sacubitril-valsartan on heart failure patients with preserved ejection fraction (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety of sacubitril-valsartan in patients with HFpEF.
 
 
 
 PubMed and Web of Science were searched without any restrictions from inception to 08 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed.
 
 
 
 Four trials, with a total of 7,008 patients were included. Compared with valsartan, sacubitril-valsartan significantly reduced the rate of HF decompensation and of the combined endpoint of HF decompensation and all-cause mortality. All-cause mortality, NYHA class improvement and rate of hyperkalemia were not significantly different between the two groups. Regarding safety, sacubitril-valsartan was more likely to increase the risk of hypotension.
 
 
 
 This meta-analysis suggests that sacubitril-valsartan may be an effective strategy to reduce HF decompensation events in patients with HFpEF.
